Split History
ETFs Holding ABUS »    ABUS Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Arbutus Biopharma is a therapeutic solutions company focused on discovering, developing and commercializing a cure for patients suffering from hepatitis B (HBV) infection. Co.'s pipeline is focused on finding a cure for chronic HBV infection. Co.'s pipeline of HBV product candidates includes: ARB-1467, ARB-1740, cccDNA formation inhibitors, core protein/ capsid assembly inhibitors, toll-like receptor (TLR) 9 Agonist (ARB-1598), surface antigen secretion inhibitors, cccDNA epigenetic modifiers, and stimulator of interferon genes (STING) agonists. Co.'s primary RNAi HBV candidate, ARB-1467, is designed to eliminate HBV surface antigen expression in patients chronically infected with HBV. According to our ABUS split history records, Arbutus Biopharma has had 1 split.
ABUS split history picture
Arbutus Biopharma (ABUS) has 1 split in our ABUS split history database. The split for ABUS took place on November 04, 2010. This was a 1 for 5 reverse split, meaning for each 5 shares of ABUS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split.

When a company such as Arbutus Biopharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the ABUS split history from start to finish, an original position size of 1000 shares would have turned into 200 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Arbutus Biopharma shares, starting with a $10,000 purchase of ABUS, presented on a split-history-adjusted basis factoring in the complete ABUS split history. ABUS split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 09/20/2007
End date: 09/19/2017
Start price/share: $6.25
End price/share: $5.55
Dividends collected/share: $0.00
Total return: -11.20%
Average Annual Total Return: -1.18%
Starting investment: $10,000.00
Ending investment: $8,880.15
Years: 10.01
Date Ratio
11/04/20101 for 5
ABUS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ACET Split History
ACHC Split History
ACST Split History
ACUR Split History
ADAP Split History
ADK Split History
ADMP Split History
ADMS Split History
ADPT Split History
ADXS Split History

Mer Telemanagement Solutions Ltd. (MTSL)
Merrimack Pharmaceuticals (MACK)
Diana Containerships Inc. (DCIX)
Farmers & Merchants Bancorp, Inc. (FMAO)
Henry Schein, Inc. (HSIC)
Intuitive Surgical, Inc. (ISRG)
Diana Containerships Inc. (DCIX)
Bridgeline Digital, Inc. (BLIN)
SUPERVALU INC. (SVU)
DryShips Inc. (DRYS)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ABUS Insider Buying

ABUS Split History | www.SplitHistory.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.